Diversified Trust Co Raises Holdings in Blueprint Medicines Corporation (NASDAQ:BPMC)

Diversified Trust Co grew its position in Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) by 105.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,226 shares of the biotechnology company's stock after buying an additional 7,808 shares during the period. Diversified Trust Co's holdings in Blueprint Medicines were worth $1,348,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BPMC. Fifth Third Bancorp boosted its stake in Blueprint Medicines by 4.7% during the first quarter. Fifth Third Bancorp now owns 3,221 shares of the biotechnology company's stock worth $285,000 after buying an additional 146 shares during the period. Torray Investment Partners LLC lifted its holdings in shares of Blueprint Medicines by 1.1% in the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock worth $1,439,000 after acquiring an additional 186 shares during the last quarter. Sherbrooke Park Advisers LLC lifted its holdings in shares of Blueprint Medicines by 8.4% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 3,374 shares of the biotechnology company's stock worth $294,000 after acquiring an additional 261 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Blueprint Medicines by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock worth $580,000 after purchasing an additional 283 shares during the period. Finally, Pitcairn Co. increased its holdings in Blueprint Medicines by 2.8% in the 4th quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock valued at $925,000 after purchasing an additional 293 shares during the last quarter.

Insider Activity at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $100.51, for a total transaction of $228,559.74. Following the transaction, the chief operating officer owned 64,718 shares in the company, valued at $6,504,806.18. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $101.14, for a total value of $505,700.00. Following the completion of the sale, the director owned 146,630 shares of the company's stock, valued at approximately $14,830,158.20. This represents a 3.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,300 shares of company stock valued at $1,249,453 over the last ninety days. Insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Down 0.1%

BPMC stock traded down $0.08 during trading on Wednesday, hitting $128.27. 1,726,663 shares of the company's stock were exchanged, compared to its average volume of 1,991,894. The business has a 50-day moving average price of $111.05 and a two-hundred day moving average price of $99.78. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $8.28 billion, a price-to-earnings ratio of -51.93 and a beta of 0.89. Blueprint Medicines Corporation has a 52-week low of $73.04 and a 52-week high of $128.52.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 64.60% and a negative net margin of 27.70%. The company had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same period in the previous year, the business posted $1.40 EPS. The firm's revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, equities research analysts expect that Blueprint Medicines Corporation will post -1.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on BPMC shares. UBS Group upped their price target on Blueprint Medicines from $88.00 to $129.00 and gave the stock a "neutral" rating in a research note on Thursday, June 5th. JMP Securities reissued a "market perform" rating on shares of Blueprint Medicines in a research note on Tuesday, June 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, May 2nd. Wolfe Research lowered shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, June 3rd. Finally, Wall Street Zen raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday, May 2nd. Eighteen equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Blueprint Medicines has a consensus rating of "Hold" and a consensus target price of $128.06.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.